EnlivenHealth Celebrates American Pharmacists Month » Learn More

Topics: DIR fees

July 26, 2021

FDS Amplicare Acquisition Will Help Support EnlivenHealth’s Retail Pharmacy Transformation Strategy

By Danny Sanchez, Vice President and General Manager, EnlivenHealth™ Our parent company Omnicell, Inc. announced this morning that it has agreed to acquire FDS Amplicare, a leading technology solutions provider for the retail pharmacy industry. Here’s a link to the Omnicell press release. The acquisition […]

Read More
June 2, 2021

Key Strategies to Mitigate DIR Fees and Improve Your Pharmacy’s Profitability

DIR fees are an unfortunate fact of life in running a pharmacy today. The lack of clarity about how much and when pharmacies get remunerated creates ongoing business challenges for an industry that already must deal with thin profit margins. Pharmacies try to budget for […]

Read More
March 24, 2021

Why Pharmacy Performance Metrics Should Focus on Collaboration

Pharmacists have long been established as America’s most trusted and accessible healthcare providers. According to a 2019 Drug Topics article, patients visit the pharmacy an average of 35 times a year compared to just four visits to other medical providers. The pharmacist’s direct working relationship with their patients […]

Read More
December 3, 2020

Reduce DIR Fees by Measurably Improving Your Patients’ Medication Adherence

Direct and indirect remuneration (DIR), originally intended to reduce prescription drug prices for seniors, has grown to exert a significant impact on the profitability of retail pharmacies. As DIR fees have risen in recent years, they have come under scrutiny for their lack of transparency […]

Read More
X

Amplicare is now part of EnlivenHealth®

X

FDSRX is now part of EnlivenHealth®